Trial
NCT02013791
Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Allergan
Collaborators
—
Condition
Dry Eye Syndromes
Intervention
Vehicle
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-05-15